MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
Actinium Pharmaceuticals General and Administrative Expenses 2011-2026 | ATNM
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Actinium Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.1 M | 13.3 M | 12 M | 8.08 M | 6.31 M | 5.52 M | 6.73 M | 9.16 M | 9.27 M | 11.5 M | 10.2 M | 3.92 M | 4.51 M | 9.62 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 13.3 M | 9.62 K | 8.04 M |
Quarterly General and Administrative Expenses Actinium Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.53 M | 2.62 M | 8.94 M | - | 2.83 M | 3.59 M | 2.96 M | - | 2.73 M | 4.56 M | 3.74 M | - | 3.07 M | 3.23 M | 1.74 M | - | 1.99 M | 1.71 M | 1.72 M | - | 1.82 M | 1.15 M | 1.53 M | - | 1.82 M | 1.08 M | 1.36 M | - | 1.97 M | 1.58 M | 1.89 M | - | 1.66 M | 2.74 M | 3.21 M | - | 1.39 M | 2.75 M | 2.22 M | - | 1.79 M | 3.55 M | 3.81 M | - | 2.89 M | 2.29 M | 2.55 M | - | 831 K | 966 K | 933 K | - | 722 K | 238 K | 1.01 K | 205 | 331 | 331 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.94 M | 205 | 2.13 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbCellera Biologics
ABCL
|
83.2 M | $ 3.52 | -1.26 % | $ 1.05 B |  Canada |
 |
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
89.7 M | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
7.17 M | - | 4.01 % | $ 150 M | Canada |
 |
Advaxis
ADXS
|
12.2 M | - | -9.65 % | $ 45.9 M | USA |
 |
AC Immune SA
ACIU
|
17.9 M | $ 3.22 | 2.88 % | $ 229 M |  Schweiz |
 |
I-Mab
IMAB
|
900 M | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | USA |
 |
AgeX Therapeutics
AGE
|
9.33 M | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M |  France |
 |
Albireo Pharma
ALBO
|
69.6 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
13.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aptorum Group Limited
APM
|
5.41 M | $ 0.8 | 1.81 % | $ 4.36 M | China |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | USA |
 |
ADC Therapeutics SA
ADCT
|
71.5 M | $ 4.13 | -1.67 % | $ 105 M | Schweiz |
 |
argenx SE
ARGX
|
308 M | $ 709.52 | 0.88 % | $ 25 B |  Niderland |
 |
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Adverum Biotechnologies
ADVM
|
63.1 M | - | - | $ 86.2 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
5.51 M | $ 3.4 | -5.82 % | $ 8.18 B |  Australia |
 |
Ascendis Pharma A/S
ASND
|
160 M | $ 228.5 | -1.09 % | $ 5 B |  Danmark |
 |
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | USA |
 |
Applied Molecular Transport
AMTI
|
37.4 M | - | - | $ 10.1 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
32.9 M | $ 6.1 | 0.83 % | $ 497 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
46.1 M | $ 6.6 | -0.45 % | $ 181 M |  Israel |
 |
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - |  Russia |
 |
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | USA |
 |
Athersys
ATHX
|
20.1 M | - | 3.77 % | $ 22.4 M | USA |
 |
Akouos
AKUS
|
22.2 M | - | 0.23 % | $ 488 M | USA |
 |
Acer Therapeutics
ACER
|
12.7 M | - | 2.71 % | $ 14 M | USA |
 |
ARCA biopharma
ABIO
|
13.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
12.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
5.92 M | - | 5.93 % | $ 314 M | Canada |
 |
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | USA |
 |
Anika Therapeutics
ANIK
|
95.8 M | $ 14.52 | 1.11 % | $ 213 M | USA |
 |
Aptinyx
APTX
|
19.8 M | - | -39.0 % | $ 4.57 M | USA |
 |
BioCardia
BCDA
|
4.4 M | $ 1.3 | 2.36 % | $ 27.5 M | USA |
 |
Aptose Biosciences
APTO
|
11.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
AVEO Pharmaceuticals
AVEO
|
60.8 M | - | - | $ 521 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
1.53 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
17.4 M | $ 2.67 | 1.14 % | $ 16.8 M | USA |
 |
Avenue Therapeutics
ATXI
|
4.64 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
46.7 M | $ 1.49 | -1.32 % | $ 380 M | Britain |
 |
Athira Pharma
ATHA
|
26.1 M | - | - | $ 269 M | USA |
 |
BioNTech SE
BNTX
|
286 M | $ 92.62 | 2.3 % | $ 27.2 B | Germany |
 |
CureVac N.V.
CVAC
|
100 M | - | - | $ 867 M | Germany |
 |
Aravive
ARAV
|
13 M | - | -13.39 % | $ 1.45 M | USA |
 |
Burford Capital Limited
BUR
|
99.3 M | $ 8.28 | 2.73 % | $ 1.35 B | Britain |
 |
AstraZeneca PLC
AZN
|
15.2 B | - | - | $ 96.9 B | Britain |